NASDAQ:BYSI BeyondSpring (BYSI) Stock Price, News & Analysis → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free BYSI Stock Alerts $2.98 -0.45 (-13.12%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$2.97▼$3.6350-Day Range$1.76▼$3.6352-Week Range$0.65▼$4.00Volume88,415 shsAverage Volume45,346 shsMarket Capitalization$116.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BeyondSpring alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About BeyondSpring Stock (NASDAQ:BYSI)BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Read More BYSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BYSI Stock News HeadlinesMay 22, 2024 | finance.yahoo.comBeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last yearMay 18, 2024 | americanbankingnews.comBeyondSpring (NASDAQ:BYSI) Trading Down 5.6%May 16, 2024 | globenewswire.comBeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsMay 3, 2024 | globenewswire.comBeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsApril 30, 2024 | msn.comBeyondSpring GAAP EPS of -$0.54, revenue of $1.75MApril 29, 2024 | globenewswire.comBeyondSpring Files 2023 Annual Report on Form 20-FApril 29, 2024 | globenewswire.comBeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsMarch 25, 2024 | globenewswire.comBeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerMarch 14, 2024 | finance.yahoo.comBYSI Oct 2024 7.500 callMarch 7, 2024 | finance.yahoo.comBYSI Mar 2024 7.500 callMarch 6, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.04%March 6, 2024 | finance.yahoo.comRetail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewardedMarch 5, 2024 | finance.yahoo.comBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsFebruary 22, 2024 | uk.finance.yahoo.comBeyondSpring Inc. (BYSI) stock historical prices & data – Yahoo FinanceJanuary 18, 2024 | morningstar.comBeyondSpring Inc BYSIJanuary 18, 2024 | finance.yahoo.comBeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KJanuary 11, 2024 | msn.comBeyondSpring gets Nasdaq delinquency noticeDecember 27, 2023 | benzinga.comBeyondSpring Stock (NASDAQ:BYSI) Insider TradesDecember 27, 2023 | benzinga.comBeyondSpring Stock (NASDAQ:BYSI) Dividends: History, Yield and DatesDecember 26, 2023 | seekingalpha.comOncternal slips after early data for lymphoma therapyDecember 20, 2023 | msn.comPassage Bio stock climbs 9% on dementia study, program updateOctober 31, 2023 | msn.comBeyondSpring regains compliance with Nasdaq minimum bid price ruleOctober 31, 2023 | finance.yahoo.comBeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsOctober 30, 2023 | finance.yahoo.comBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 26, 2023 | markets.businessinsider.comSEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumSee More Headlines Receive BYSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/29/2021Today5/26/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BYSI CUSIPN/A CIK1677940 Webwww.beyondspringpharma.com Phone(646) 305-6387Fax1-646-882-4228Employees36Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.31 Quick Ratio2.31 Sales & Book Value Annual Sales$1.75 million Price / Sales66.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-3.27Miscellaneous Outstanding Shares39,030,000Free Float27,590,000Market Cap$116.31 million OptionableOptionable Beta0.32 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Lan Huang Ph.D. (Age 53)Co-Founder, Chairman & CEO Dr. June Lu Ph.D.Chief Scientific OfficerMr. Linqing JiaCo-FounderStephen KilmerHead of Investor RelationsMr. Gregg RussoSenior Vice President of Human ResourcesKey CompetitorsvTv TherapeuticsNASDAQ:VTVTAssembly BiosciencesNASDAQ:ASMBAVROBIONASDAQ:AVROProQR TherapeuticsNASDAQ:PRQRBrainstorm Cell TherapeuticsNASDAQ:BCLIView All CompetitorsInstitutional OwnershipAcadian Asset Management LLCSold 12,204 shares on 5/10/2024Ownership: 0.058%SG Americas Securities LLCBought 17,539 shares on 5/7/2024Ownership: 0.045%View All Institutional Transactions BYSI Stock Analysis - Frequently Asked Questions How have BYSI shares performed in 2024? BeyondSpring's stock was trading at $0.90 on January 1st, 2024. Since then, BYSI shares have increased by 231.1% and is now trading at $2.98. View the best growth stocks for 2024 here. When is BeyondSpring's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our BYSI earnings forecast. How were BeyondSpring's earnings last quarter? BeyondSpring Inc. (NASDAQ:BYSI) issued its quarterly earnings data on Wednesday, December, 29th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.11. The business earned $0.34 million during the quarter, compared to analyst estimates of $0.34 million. What other stocks do shareholders of BeyondSpring own? Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX). When did BeyondSpring IPO? BeyondSpring (BYSI) raised $4 million in an IPO on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO. Who are BeyondSpring's major shareholders? BeyondSpring's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.06%), SG Americas Securities LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of BeyondSpring? Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BYSI) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap Profits$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyElon’s New Device is About to Shock the WorldInvestorPlaceNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.